Minocycline,Metronidazole
Phase 3Small molecule
Minocycline,Metronidazole is one of 17 small molecule programs targeting Helicobacter Pylori Infection. It is currently in Phase 3.
1
Indications
3
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
30 competitors in Helicobacter Pylori Infection
#DrugCompanyPhaseTrials
1Biaxin
AbbVieApproved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Flagyl
DDePuy Orthopaedics
Approved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Takecab
PPhathom Pharmaceuticals, Inc.
Approved
Achromycin V
WWyeth-Lederle Vaccines
Approved
Levaquin
WWim Janssens
Approved
Potassium Citrate
MMission Pharmacal
Approved
Tegoprazan
SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Phase 3
Vonoprazan
TakedaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Helicobacter Pylori Infection1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Minocycline,Metronidazole. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details